EXCLUSIVE: Oragenics Tells Benzinga Co. Completes Spray Dry Drug Manufacturing And Intranasal Device Filling In Anticipation Of Phase IIa Clinical Trial In Concussed Patients
Portfolio Pulse from Benzinga Newsdesk
Oragenics has completed the spray dry drug manufacturing and intranasal device filling in preparation for a Phase IIa clinical trial targeting concussed patients.
August 21, 2024 | 12:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oragenics has finalized the manufacturing of its spray dry drug and intranasal device, setting the stage for a Phase IIa clinical trial in concussed patients.
The completion of drug manufacturing and device filling is a significant milestone for Oragenics as it prepares for a Phase IIa clinical trial. This progress could positively influence investor sentiment and potentially lead to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100